Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.01)
# 3,062
Out of 5,067 analysts
119
Total ratings
31.82%
Success rate
-3.78%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $9.84 | +32.11% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $14.10 | +126.95% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $5.39 | +66.98% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $84.28 | +12.72% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $19.49 | +28.27% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $6.78 | +76.99% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $7.41 | +61.94% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $7.46 | -6.10% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.06 | +88.68% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $16.26 | +4.55% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $4.13 | +117.92% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $19.70 | +133.50% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.60 | +1,233.56% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $28.39 | -15.46% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.69 | +136.69% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.73 | +141.61% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $3.75 | +460.00% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.54 | +252.42% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $2.50 | +40.00% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.33 | +653.01% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.96 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.32 | +2,562.34% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $9.84
Upside: +32.11%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $14.10
Upside: +126.95%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.39
Upside: +66.98%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $84.28
Upside: +12.72%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $19.49
Upside: +28.27%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $6.78
Upside: +76.99%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $7.41
Upside: +61.94%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $7.46
Upside: -6.10%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.06
Upside: +88.68%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $16.26
Upside: +4.55%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $4.13
Upside: +117.92%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $19.70
Upside: +133.50%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $0.60
Upside: +1,233.56%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $28.39
Upside: -15.46%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.69
Upside: +136.69%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $3.73
Upside: +141.61%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $3.75
Upside: +460.00%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.54
Upside: +252.42%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $2.50
Upside: +40.00%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.33
Upside: +653.01%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.96
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.32
Upside: +2,562.34%